TriSalus Life Sciences (TLSI) Financial Statements & Analysis

TriSalus Life Sciences (TLSI) Income Statement

TriSalus Life Sciences reported revenue of $45.15M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 53.4% from $29.43M a year earlier. TriSalus Life Sciences posted a net loss of $69.69M, compared with a net loss of $33.23M a year earlier. Gross margin was 84.6% and operating margin -59.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $11.41M, up 1.7% from the same quarter a year earlier.

TriSalus Life Sciences Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

TriSalus Life Sciences, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	45.15	29.43	18.51	18.51	12.40	8.40	0.00
Cost of Revenue	6.97	4.10	2.61	2.61	2.26	1.19	0.00
Gross Profit	38.19	25.33	15.91	15.91	10.14	7.21	0.00
Operating Expenses
Research & Development	14.97	17.69	29.84	29.84	21.36	14.22	0.00
Selling, General & Administrative	50.17	43.81	40.55	36.25	25.22	17.02	0.11
Operating Expenses	65.13	61.49	70.38	70.38	46.58	31.24	0.11
Operating Income	-26.95	-36.17	-54.48	-54.48	-36.44	-24.03	-0.11
Other Income/Expense
Interest Income	0.56	0.40	0.43	0.43	0.18	0.00	0.00
Interest Expense	5.54	3.09	0.02	-0.02	0.00	1.76	0.00
Other Income/Expense	-12.27	6.13	-4.88	-4.88	-10.74	-4.81	-0.60
Income
Income Before Tax	-39.22	-30.04	-59.35	-59.35	-47.18	-28.84	-0.71
Income Tax Expense	0.01	0.01	0.01	0.01	0.01	0.00	0.00
Net Income	-69.69	-33.23	-59.36	-63.60	-47.19	-28.85	-31.83
Net Income - Continuous Operations	-39.23	-33.23	-59.36	-59.36	-47.19	-28.85	-31.83
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-26.32	-32.39	-58.65	-49.49	-46.76	-26.62	-0.71
EBIT	-26.95	-36.17	-	-50.18	-47.18	-27.08	-25.65
Depreciation & Amortization	0.63	0.74	0.68	0.68	0.41	0.46	0.00
Earnings Per Share
Basic EPS	-2.00	-1.00	-2.00	-7.00	-2.00	-1.00	-
Diluted EPS	-2.00	-1.00	-2.00	-7.00	-2.00	-1.00	-
Basic Shares Outstanding	37.90	26.50	26.47	9.40	29.61	31.25	30.56
Diluted Shares Outstanding	37.90	26.50	26.47	9.40	29.61	31.25	30.56

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TriSalus Life Sciences Financial Statements

What was TriSalus Life Sciences's revenue in fiscal 2025?

TriSalus Life Sciences reported revenue of $45.15M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 53.4% from $29.43M a year earlier.

Is TriSalus Life Sciences profitable?

No. TriSalus Life Sciences reported a net loss of $69.69M in fiscal 2025. In fiscal 2024 it lost $33.23M.

What is TriSalus Life Sciences's operating margin?

TriSalus Life Sciences's operating income was −$26.95M on revenue of $45.15M in fiscal 2025, an operating margin of -59.7%, compared with -122.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition